The stock of Catalyst Pharmaceuticals Inc (CPRX) has gone up by 6.65% for the week, with a 16.42% rise in the past month and a 25.81% rise in the past quarter. The volatility ratio for the week is 3.26%, and the volatility levels for the past 30 days are 2.89% for CPRX. The simple moving average for the past 20 days is 7.81% for CPRX’s stock, with a 35.39% simple moving average for the past 200 days.
Is It Worth Investing in Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) Right Now?
The price-to-earnings ratio for Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) is above average at 19.84x, Company’s 36-month beta value is 0.76.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CPRX is 102.43M, and currently, short sellers hold a 5.82% ratio of that floaft. The average trading volume of CPRX on November 08, 2024 was 984.36K shares.
CPRX) stock’s latest price update
The stock price of Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) has surged by 2.38 when compared to previous closing price of 22.71, but the company has seen a 6.65% gain in its stock price over the last five trading sessions. zacks.com reported 2024-11-07 that Catalyst stock gains on strong third-quarter results, beating earnings and revenue estimates, primarily driven by Firdapse sales. Management raises sales guidance.
Analysts’ Opinion of CPRX
Many brokerage firms have already submitted their reports for CPRX stocks, with Citigroup repeating the rating for CPRX by listing it as a “Buy.” The predicted price for CPRX in the upcoming period, according to Citigroup is $27 based on the research report published on March 14, 2024 of the current year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see CPRX reach a price target of $23. The rating they have provided for CPRX stocks is “Buy” according to the report published on March 07th, 2024.
Oppenheimer gave a rating of “Outperform” to CPRX, setting the target price at $30 in the report published on December 21st of the previous year.
CPRX Trading at 12.51% from the 50-Day Moving Average
After a stumble in the market that brought CPRX to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 0.56% of gains for the given period.
Volatility was left at 2.89%, however, over the last 30 days, the volatility rate increased by 3.26%, as shares surge +16.78% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.08% upper at present.
During the last 5 trading sessions, CPRX rose by +6.65%, which changed the moving average for the period of 200-days by +59.25% in comparison to the 20-day moving average, which settled at $21.57. In addition, Catalyst Pharmaceuticals Inc saw 38.31% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CPRX starting from Tierney David S, who sale 15,000 shares at the price of $20.10 back on Aug 21 ’24. After this action, Tierney David S now owns 348,874 shares of Catalyst Pharmaceuticals Inc, valued at $301,455 using the latest closing price.
Miller Steve, the Chief Op. & Scientific Officer of Catalyst Pharmaceuticals Inc, sale 150,000 shares at $20.35 during a trade that took place back on Aug 20 ’24, which means that Miller Steve is holding 675,124 shares at $3,052,900 based on the most recent closing price.
Stock Fundamentals for CPRX
Current profitability levels for the company are sitting at:
- 0.38 for the present operating margin
- 0.82 for the gross margin
The net margin for Catalyst Pharmaceuticals Inc stands at 0.31. The total capital return value is set at 0.26. Equity return is now at value 28.29, with 24.10 for asset returns.
Based on Catalyst Pharmaceuticals Inc (CPRX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at 77.74. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is 102.1.
Currently, EBITDA for the company is 119.95 million with net debt to EBITDA at -2.17. When we switch over and look at the enterprise to sales, we see a ratio of 5.06. The receivables turnover for the company is 7.86for trailing twelve months and the total asset turnover is 0.59. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.11.
Conclusion
In a nutshell, Catalyst Pharmaceuticals Inc (CPRX) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
